The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Eric Trump on Tuesday described Bitcoin as a “modern-day gold,” calling it a liquid store of value that can act as a hedge to real estate and other assets. Related Reading: XRP’s Biggest Rally Yet? Analyst Projects $20+ In October 2025 According to reports, the remark came during a TV appearance on CNBC’s Squawk Box, tied to the launch of American Bitcoin, the mining and treasury firm he helped start. Company Holdings And Strategy Based on public filings and company summaries, American Bitcoin has accumulated 2,443 BTC on its balance sheet. That stash has been valued in the low hundreds of millions of dollars at recent spot prices. The firm mixes large-scale mining with the goal of holding Bitcoin as a strategic reserve, which it says will help it grow both production and asset holdings over time. Eric Trump’s comments were direct. He told viewers that institutions are treating Bitcoin more like a store of value than a fringe idea, and he warned firms that resist blockchain adoption. The tone was strong at times, and the line about Bitcoin being a modern equivalent of gold was used to frame American Bitcoin’s role as both miner and holder.   Eric Trump has said: bitcoin is modern-day gold — unusual_whales (@unusual_whales) September 16, 2025 How The Company Went Public American Bitcoin moved toward a public listing via an all-stock merger with Gryphon Digital Mining earlier this year, a deal that kept most of the original shareholders in control and positioned the new entity for a Nasdaq debut. Reports show that mining partner Hut 8 holds a large ownership stake, leaving the Trump family and other backers with a minority share. The listing brought fresh attention and capital to the firm as it began trading under the ticker ABTC. Market watchers say the firm’s public debut highlights two trends: mining companies are trying to grow by both producing and holding Bitcoin, and political ties are bringing more headlines to crypto firms. Some analysts point out that holding large amounts of Bitcoin on the balance sheet exposes a company to price swings, while supporters argue it aligns incentives between miners and investors. Related Reading: Ethereum Bulls Target $8,500 With Big Money Backing The Move – Details Reaction And Possible Risks Based on coverage of the launch, investors have reacted with both enthusiasm and caution. Supporters praise the prospect of a US-based miner that aims to be transparent and aggressive about building a reserve. Critics point to governance questions, possible conflicts tied to high-profile backers, and the usual risks of a volatile asset being held on corporate balance sheets. Eric Trump’s remark that Bitcoin has taken gold’s role in today’s world reflects both his belief in its value and American Bitcoin’s strategy of mining and holding. Whether that view sticks will depend on how investors and institutions respond in the months ahead. Featured image from Meta, chart from TradingView
Share
NewsBTC2025/09/18 06:00
Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

The post Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps appeared on BitcoinEthereumNews.com. The Federal Reserve has made its first Fed rate cut this year following today’s FOMC meeting, lowering interest rates by 25 basis points (bps). This comes in line with expectations, while the crypto market awaits Fed Chair Jerome Powell’s speech for guidance on the committee’s stance moving forward. FOMC Makes First Fed Rate Cut This Year With 25 Bps Cut In a press release, the committee announced that it has decided to lower the target range for the federal funds rate by 25 bps from between 4.25% and 4.5% to 4% and 4.25%. This comes in line with expectations as market participants were pricing in a 25 bps cut, as against a 50 bps cut. This marks the first Fed rate cut this year, with the last cut before this coming last year in December. Notably, the Fed also made the first cut last year in September, although it was a 50 bps cut back then. All Fed officials voted in favor of a 25 bps cut except Stephen Miran, who dissented in favor of a 50 bps cut. This rate cut decision comes amid concerns that the labor market may be softening, with recent U.S. jobs data pointing to a weak labor market. The committee noted in the release that job gains have slowed, and that the unemployment rate has edged up but remains low. They added that inflation has moved up and remains somewhat elevated. Fed Chair Jerome Powell had also already signaled at the Jackson Hole Conference that they were likely to lower interest rates with the downside risk in the labor market rising. The committee reiterated this in the release that downside risks to employment have risen. Before the Fed rate cut decision, experts weighed in on whether the FOMC should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 04:36
UK Looks to US to Adopt More Crypto-Friendly Approach

UK Looks to US to Adopt More Crypto-Friendly Approach

The post UK Looks to US to Adopt More Crypto-Friendly Approach appeared on BitcoinEthereumNews.com. The UK and US are reportedly preparing to deepen cooperation on digital assets, with Britain looking to copy the Trump administration’s crypto-friendly stance in a bid to boost innovation.  UK Chancellor Rachel Reeves and US Treasury Secretary Scott Bessent discussed on Tuesday how the two nations could strengthen their coordination on crypto, the Financial Times reported on Tuesday, citing people familiar with the matter.  The discussions also involved representatives from crypto companies, including Coinbase, Circle Internet Group and Ripple, with executives from the Bank of America, Barclays and Citi also attending, according to the report. The agreement was made “last-minute” after crypto advocacy groups urged the UK government on Thursday to adopt a more open stance toward the industry, claiming its cautious approach to the sector has left the country lagging in innovation and policy.  Source: Rachel Reeves Deal to include stablecoins, look to unlock adoption Any deal between the countries is likely to include stablecoins, the Financial Times reported, an area of crypto that US President Donald Trump made a policy priority and in which his family has significant business interests. The Financial Times reported on Monday that UK crypto advocacy groups also slammed the Bank of England’s proposal to limit individual stablecoin holdings to between 10,000 British pounds ($13,650) and 20,000 pounds ($27,300), claiming it would be difficult and expensive to implement. UK banks appear to have slowed adoption too, with around 40% of 2,000 recently surveyed crypto investors saying that their banks had either blocked or delayed a payment to a crypto provider.  Many of these actions have been linked to concerns over volatility, fraud and scams. The UK has made some progress on crypto regulation recently, proposing a framework in May that would see crypto exchanges, dealers, and agents treated similarly to traditional finance firms, with…
Share
BitcoinEthereumNews2025/09/18 02:21